Currently, new agents for AD such as H4R antagonist [17], Janus kinase (JAK) inhibitors [31], JAK-spleen tyrosine kinase inhibitor [32], anti-OX40 antibody [33] and IL-22 monoclonal antibody [34] are being developed. Here, IL22 is linked to Alzheimer disease.